Latest Wave Life Sciences News & Updates

See the latest news and media coverage for Wave Life Sciences. We track all announcements, press releases, and industry mentions in real time, all in one place.

Wave Life Sciences

RNA medicines developer

wavelifesciences.com

Headquarters: Cambridge, United States
Founded year: 2012
Company type: Public company
Number of employees: 350–500
Industry: Pharmaceuticals

Last updated Today

Latest news about Wave Life Sciences

In short: Wave Life Sciences completed its redomiciliation to Delaware and initiated a Phase 2a trial for its obesity drug candidate WVE-007.

Company announcements

August 10 Wave Life Sciences

Wave Life Sciences announces completion of redomiciliation to Delaware

The parent company changed from a Singapore entity to a Delaware corporation through a scheme of arrangement, with shares exchanged one-for-one and trading continuing under WVE.

August 5 Wave Life Sciences

Wave Life Sciences announces expected completion date for redomiciliation

The scheme was approved by Singapore's High Court on July 14, 2026, and will become effective after market close on August 7, 2026, upon regulatory filing.

July 23 Wave Life Sciences

Wave Life Sciences will host Q2 2026 financial results webcast

The webcast is on July 30, 2026 at 8:30 a.m. ET. An archived version will be available.

July 7 Wave Life Sciences

Wave Life Sciences announces Singapore court hearing for redomiciliation

The hearing is set for July 14, 2026, to consider approval of the redomiciliation to Delaware.

Media coverage

Yesterday CGT Live

Wave Life Sciences' Antisense Oligonucleotide WVE-003 Demonstrates Ability to Lower Mutant Huntingtin in Phase 1b/2a Trial | CGTlive®

The placebo-controlled multidose portion of the SELECT-HD trial included 23 patients with Huntington Disease in total.

August 13 Yahoo Finance

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...

August 3 Precision Medicine Online

Wave Life Sciences Weighing Duchenne Partnerships Before Pursuing FDA Filing

The biotech, which previously said it would seek accelerated approval for WVE-N531, is evaluating the regulatory and commercial landscape.

July 31 GuruFocus

WVE Maintained by Mizuho -- Price Target Lowered to $23.00

WAVE Life Sciences (WVE) Analyst Rating Update On October 3, 2023, Mizuho maintained an "Outperform"...

Never miss news about Wave Life Sciences

Track Wave Life Sciences and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Wave Life Sciences competitors & trending companies

Browse news for competitors to Wave Life Sciences and other trending companies.